

Direct Compressible Granules


| Product | Strength in mg | Unit Wt mg/unit (Tab/Caps) | No of Tab's in 1kg of DC Granules | BE | CDP |
|--|----------------|----------------------------|-----------------------------------|----|-----|
| Apixaban 2.50% w/w | 5 mg Tabs | 100 | 10,000 | | ✓ |
| Apixaban 2.50% w/w | 10 mg Tabs | 200 | 5,000 | | ✓ |
| Bilastine 20% w/w | 20 mg Tabs | 100 | 10,000 | ✓ | ✓ |
| Bempidoic 55.38% w/w | 180 mg Tabs | 325 | 3,077 | ✓ | ✓ |
| Diosmin + Hesperidin Tablet 71.42% w/w | 500 mg Tabs | 700 | 1,429 | | ✓ |
| Diosmin + Hesperidin Tablet 71.42% w/w | 1000 mg Tabs | 1400 | 714 | | ✓ |
| Dapagliflozin Tablet 4% w/w | 5 mg Tabs | 125 | 8,000 | | ✓ |
| Dapagliflozin Tablet 4% w/w | 10 mg Tabs | 150 | 6,667 | | ✓ |
| Dapagliflozin 0.588% w/w + Metformin 58.82% w/w Tablet | 10 mg + 1000mg | 1700 | 588 | | |
| Levodopa 68.97% w/w + Benserazide 19.69% w/w | 100 mg + 25 mg | 145 | 6,897 | ✓ | ✓ |
| Levodopa 68.97% w/w + Benserazide 19.69% w/w | 200 mg + 50 mg | 290 | 3,448 | ✓ | ✓ |
| Linaclotide DCG 0.09667% | 72 mcg | 75 | 13,333 | | ✓ |
| Linaclotide DCG 0.09667% | 145 mcg | 150 | 6,666 | | ✓ |
| Linaclotide DCG 0.09667% | 290 mcg | 300 | 3,333 | | ✓ |
| Polmacoxib 2.11% w/w | 2 mg Caps | 95 | 10,526 | ✓ | ✓ |
| Topiroxostat 28.57% w/w | 20 mg Tabs | 70 | 14,286 | ✓ | ✓ |
| Topiroxostat 28.57% w/w | 40 mg Tabs | 140 | 7,143 | ✓ | ✓ |
| Topiroxostat 28.57% w/w | 60 mg Tabs | 210 | 4,762 | ✓ | ✓ |
| Tofacitinib 2.50% w/w | 5 mg Tabs | 200 | 5,000 | | ✓ |
| Vortioxetine 3.33% w/w | 5 mg Tabs | 150 | 6,667 | | ✓ |
| Vortioxetine 6.66% w/w | 10 mg Tabs | 150 | 6,667 | | ✓ |
| Vortioxetine 13.33% w/w | 15 mg Tabs | 150 | 6,667 | | ✓ |

Under Development

- Resmetirom
- Gefapixant
- Eluxadoline
- Elobixibat

PRODUCTS PROTECTED BY PATENTS ARE NOT OFFERED FOR SALE IN COUNTRIES WHERE THE SALE OF SUCH PRODUCTS CONSTITUTES PATENT INFRINGEMENT. ALL LIABILITIES ARISING DUE TO SUCH PATENT INFRINGEMENT LIES SOLELY WITH THE BUYER.

To Know More
Scan the QR Code



More Than
23 Years of Experience

Exporting to
More Than 65 Countries

State-of-the-Art
Manufacturing Facilities

API & Formulations
Dedicated R&D Centres